{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T02:13:04Z","timestamp":1791511984506,"version":"4.3.4"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,4,10]]},"DOI":"10.7759\/cureus.106825","type":"journal-article","created":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T05:39:56Z","timestamp":1775885996000},"source":"Crossref","is-referenced-by-count":1,"title":["A Review of Yellow Fever: Epidemiology, Pathogenesis, Clinical Manifestations, Treatment, Prevention, and Prognosis"],"prefix":"10.7759","author":[{"given":"Farah","family":"Ebrahim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samina","family":"Somji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reena","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salim","family":"Surani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.idc.2004.01.007","article-title":"Yellow fever in the Americas","volume":"18","author":"Bryan CS","year":"2004","unstructured":"Bryan CS, Moss SW, Kahn RJ. Yellow fever in the Americas. Infect Dis Clin North Am. 2004, 18:275-92. 10.1016\/j.idc.2004.01.007","journal-title":"Infect Dis Clin North Am"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(20)30170-5","article-title":"Prevention of yellow fever in travellers: an update","volume":"20","author":"Reno E","year":"2020","unstructured":"Reno E, Quan NG, Franco-Paredes C, Chastain DB, Chauhan L, Rodriguez-Morales AJ, Henao-Mart\u00ednez AF. Prevention of yellow fever in travellers: an update. Lancet Infect Dis. 2020, 20:129-37. 10.1016\/S1473-3099(20)30170-5","journal-title":"Lancet Infect Dis"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.64670","article-title":"The global burden of yellow fever","volume":"10","author":"Gaythorpe KA","year":"2021","unstructured":"Gaythorpe KA, Hamlet A, Jean K, Garkauskas Ramos D, Cibrelus L, Garske T, Ferguson N. The global burden of yellow fever. eLife. 2021, 10:64670. 10.7554\/eLife.64670","journal-title":"eLife"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.53854\/liim-3204-3","article-title":"Yellow fever: global impact, epidemiology, pathogenesis, and integrated prevention approaches","volume":"32","author":"Srivastava S","year":"2024","unstructured":"Srivastava S, Dhoundiyal S, Kumar S, et al.. Yellow fever: global impact, epidemiology, pathogenesis, and integrated prevention approaches. Infez Med. 2024, 32:434-50. 10.53854\/liim-3204-3","journal-title":"Infez Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.amsu.2022.104537","article-title":"Yellow fever outbreak in Kenya: a review","volume":"82","author":"Uwishema O","year":"2022","unstructured":"Uwishema O, Eneh SC, Chiburoma AG, et al.. Yellow fever outbreak in Kenya: a review. Ann Med Surg (Lond). 2022, 82:104537. 10.1016\/j.amsu.2022.104537","journal-title":"Ann Med Surg (Lond)"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines10030372","article-title":"Yellow fever: origin, epidemiology, preventive strategies and future prospects","volume":"10","author":"Gianchecchi E","year":"2022","unstructured":"Gianchecchi E, Cianchi V, Torelli A, Montomoli E. Yellow fever: origin, epidemiology, preventive strategies and future prospects. Vaccines (Basel). 2022, 10:372. 10.3390\/vaccines10030372","journal-title":"Vaccines (Basel)"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0010610","article-title":"Epidemiology of yellow fever virus in humans, arthropods, and non-human primates in sub-Saharan Africa: a systematic review and meta-analysis","volume":"16","author":"Oyono MG","year":"2022","unstructured":"Oyono MG, Kenmoe S, Abanda NN, et al.. Epidemiology of yellow fever virus in humans, arthropods, and non-human primates in sub-Saharan Africa: a systematic review and meta-analysis. PLoS Negl Trop Dis. 2022, 16:e0010610. 10.1371\/journal.pntd.0010610","journal-title":"PLoS Negl Trop Dis"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines12121424","article-title":"Reaching forest workers with yellow fever vaccine through engagement of the private sector in Central African Republic","volume":"12","author":"Noufack G","year":"2024","unstructured":"Noufack G, Bissengue P, Zobanga JK, Malingao JS, Keita M, Razaiarimanga MC, Raguenaud ME. Reaching forest workers with yellow fever vaccine through engagement of the private sector in Central African Republic. Vaccines (Basel). 2024, 12:1424. 10.3390\/vaccines12121424","journal-title":"Vaccines (Basel)"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.12968\/pnur.2018.29.Sup6.S3","article-title":"Yellow fever: current outbreak in Brazil and cases reported in unvaccinated travellers","volume":"29","author":"Gawthrop M","year":"2018","unstructured":"Gawthrop M. Yellow fever: current outbreak in Brazil and cases reported in unvaccinated travellers. Practice Nursing. 2018, 29:3-7. 10.12968\/pnur.2018.29.Sup6.S3","journal-title":"Practice Nursing"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1002\/hsr2.1924","article-title":"Assessment of the yellow fever outbreak in Angola from December 2015 through December 2016: a retrospective study","volume":"7","author":"Manuel E","year":"2024","unstructured":"Manuel E, Armando A, Francisco M, et al.. Assessment of the yellow fever outbreak in Angola from December 2015 through December 2016: a retrospective study. Health Sci Rep. 2024, 7:e1924. 10.1002\/hsr2.1924","journal-title":"Health Sci Rep"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-018-3440-y","article-title":"Outbreak of yellow fever in central and southwestern Uganda, February-May 2016","volume":"18","author":"Kwagonza L","year":"2018","unstructured":"Kwagonza L, Masiira B, Kyobe-Bosa H, et al.. Outbreak of yellow fever in central and southwestern Uganda, February-May 2016. BMC Infect Dis. 2018, 18:548. 10.1186\/s12879-018-3440-y","journal-title":"BMC Infect Dis"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(23)00114-7","article-title":"Immunogenicity and safety of fractional doses of 17D-213 yellow fever vaccine in HIV-infected people in Kenya (YEFE): a randomised, double-blind, non-inferiority substudy of a phase 4 trial","volume":"23","author":"Kimathi D","year":"2023","unstructured":"Kimathi D, Juan-Giner A, Orindi B, et al.. Immunogenicity and safety of fractional doses of 17D-213 yellow fever vaccine in HIV-infected people in Kenya (YEFE): a randomised, double-blind, non-inferiority substudy of a phase 4 trial. Lancet Infect Dis. 2023, 23:974-82. 10.1016\/S1473-3099(23)00114-7","journal-title":"Lancet Infect Dis"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.3390\/insects9040158","article-title":"Effects of the environmental temperature on Aedes aegypti and Aedes albopictus mosquitoes: a review","volume":"9","author":"Reinhold JM","year":"2018","unstructured":"Reinhold JM, Lazzari CR, Lahond\u00e8re C. Effects of the environmental temperature on Aedes aegypti and Aedes albopictus mosquitoes: a review. Insects. 2018, 9:158. 10.3390\/insects9040158","journal-title":"Insects"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1080\/17441692.2025.2519659","article-title":"Fever pitch: coloniality and contention within community health's yellow fever response in Kenya","volume":"20","author":"Dodworth K","year":"2025","unstructured":"Dodworth K, Mukungu BN. Fever pitch: coloniality and contention within community health's yellow fever response in Kenya. Glob Public Health. 2025, 20:2519659. 10.1080\/17441692.2025.2519659","journal-title":"Glob Public Health"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2024.2391596","article-title":"Yellow fever vaccine coverage and associated factors among under-five children in Kenya: data from Kenyan Demographic and Health Survey 2022","volume":"20","author":"Ali MS","year":"2024","unstructured":"Ali MS, Mekonen EG. Yellow fever vaccine coverage and associated factors among under-five children in Kenya: data from Kenyan Demographic and Health Survey 2022. Hum Vaccin Immunother. 2024, 20:2391596. 10.1080\/21645515.2024.2391596","journal-title":"Hum Vaccin Immunother"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1080\/22221751.2022.2063762","article-title":"Risk assessment of urban yellow fever virus transmission in Kenya: is Aedes aegypti an efficient vector?","volume":"11","author":"Agha SB","year":"2022","unstructured":"Agha SB, Tchouassi DP, Turell MJ, Bastos AD, Sang R. Risk assessment of urban yellow fever virus transmission in Kenya: is Aedes aegypti an efficient vector?. Emerg Microbes Infect. 2022, 11:1272-80. 10.1080\/22221751.2022.2063762","journal-title":"Emerg Microbes Infect"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0008974","article-title":"Seasonal and inter-annual drivers of yellow fever transmission in South America","volume":"15","author":"Hamlet A","year":"2021","unstructured":"Hamlet A, Gaythorpe KA, Garske T, Ferguson NM. Seasonal and inter-annual drivers of yellow fever transmission in South America. PLoS Negl Trop Dis. 2021, 15:e0008974. 10.1371\/journal.pntd.0008974","journal-title":"PLoS Negl Trop Dis"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/s1286-4579(02)00028-x","article-title":"The epidemiology of yellow fever in Africa","volume":"4","author":"Mutebi JP","year":"2002","unstructured":"Mutebi JP, Barrett ADT. The epidemiology of yellow fever in Africa. Microbes Infect. 2002, 4:1459-68. 10.1016\/s1286-4579(02)00028-x","journal-title":"Microbes Infect"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.scitotenv.2022.157566","article-title":"Past, present and future distribution of the yellow fever mosquito Aedes aegypti: the European paradox","volume":"847","author":"Wint W","year":"2022","unstructured":"Wint W, Jones P, Kraemer M, Alexander N, Schaffner F. Past, present and future distribution of the yellow fever mosquito Aedes aegypti: the European paradox. Sci Total Environ. 2022, 847:157566. 10.1016\/j.scitotenv.2022.157566","journal-title":"Sci Total Environ"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.17-0866","article-title":"Mosquito-borne human viral diseases: why Aedes aegypti?","volume":"98","author":"Powell JR","year":"2018","unstructured":"Powell JR. Mosquito-borne human viral diseases: why Aedes aegypti?. Am J Trop Med Hyg. 2018, 98:1563-5. 10.4269\/ajtmh.17-0866","journal-title":"Am J Trop Med Hyg"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.3390\/v16010084","article-title":"Mechanisms of yellow fever transmission: gleaning the overlooked records of importance and identifying problems, puzzles, serious issues, surprises and research questions","volume":"16","author":"Kuno G","year":"2024","unstructured":"Kuno G. Mechanisms of yellow fever transmission: gleaning the overlooked records of importance and identifying problems, puzzles, serious issues, surprises and research questions. Viruses. 2024, 16:10084. 10.3390\/v16010084","journal-title":"Viruses"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(01)00016-0","article-title":"Yellow fever: an update","volume":"1","author":"Monath TP","year":"2001","unstructured":"Monath TP. Yellow fever: an update. Lancet Infect Dis. 2001, 1:11-20. 10.1016\/S1473-3099(01)00016-0","journal-title":"Lancet Infect Dis"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.cll.2010.01.001","article-title":"Yellow fever: a reemerging threat","volume":"30","author":"Gardner CL","year":"2010","unstructured":"Gardner CL, Ryman KD. Yellow fever: a reemerging threat. Clin Lab Med. 2010, 30:237-60. 10.1016\/j.cll.2010.01.001","journal-title":"Clin Lab Med"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.3390\/v11100960","article-title":"Yellow fever: integrating current knowledge with technological innovations to identify strategies for controlling a re-emerging virus","volume":"11","author":"Kleinert RD","year":"2019","unstructured":"Kleinert RD, Montoya-Diaz E, Khera T, et al.. Yellow fever: integrating current knowledge with technological innovations to identify strategies for controlling a re-emerging virus. Viruses. 2019, 11:960. 10.3390\/v11100960","journal-title":"Viruses"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/j.virol.2004.10.034","article-title":"Construction and applications of yellow fever virus replicons","volume":"331","author":"Jones CT","year":"2005","unstructured":"Jones CT, Patkar CG, Kuhn RJ. Construction and applications of yellow fever virus replicons. Virology. 2005, 331:247-59. 10.1016\/j.virol.2004.10.034","journal-title":"Virology"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200103083441001","article-title":"Efficacy and safety of recombinant human activated protein C for severe sepsis","volume":"344","author":"Bernard GR","year":"2001","unstructured":"Bernard GR, Vincent JL, Laterre PF, et al.. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med. 2001, 344:699-709. 10.1056\/NEJM200103083441001","journal-title":"N Engl J Med"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1038\/s41426-018-0128-8","article-title":"Yellow fever in the diagnostics laboratory","volume":"7","author":"Domingo C","year":"2018","unstructured":"Domingo C, Charrel RN, Schmidt-Chanasit J, Zeller H, Reusken C. Yellow fever in the diagnostics laboratory. Emerg Microbes Infect. 2018, 7:129. 10.1038\/s41426-018-0128-8","journal-title":"Emerg Microbes Infect"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/164.6.1119","article-title":"Prospective, double-blind, concurrent, placebo-controlled clinical trial of intravenous ribavirin therapy of hemorrhagic fever with renal syndrome","volume":"164","author":"Huggins JW","year":"1991","unstructured":"Huggins JW, Hsiang CM, Cosgriff TM, et al.. Prospective, double-blind, concurrent, placebo-controlled clinical trial of intravenous ribavirin therapy of hemorrhagic fever with renal syndrome. J Infect Dis. 1991, 164:1119-27. 10.1093\/infdis\/164.6.1119","journal-title":"J Infect Dis"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2012.12.002","article-title":"Experimental therapies for yellow fever","volume":"97","author":"Julander JG","year":"2013","unstructured":"Julander JG. Experimental therapies for yellow fever. Antiviral Res. 2013, 97:169-79. 10.1016\/j.antiviral.2012.12.002","journal-title":"Antiviral Res"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1111\/tmi.13674","article-title":"Systematic review: yellow fever control through environmental management mechanisms","volume":"26","author":"Heinz S","year":"2021","unstructured":"Heinz S, Kolimenakis A, Horstick O, Yakob L, Michaelakis A, Lowery Wilson M. Systematic review: yellow fever control through environmental management mechanisms. Trop Med Int Health. 2021, 26:1411-8. 10.1111\/tmi.13674","journal-title":"Trop Med Int Health"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0008428","article-title":"A greener vision for vector control: the example of the Singapore dengue control programme","volume":"14","author":"Sim S","year":"2020","unstructured":"Sim S, Ng LC, Lindsay SW, Wilson AL. A greener vision for vector control: the example of the Singapore dengue control programme. PLoS Negl Trop Dis. 2020, 14:e0008428. 10.1371\/journal.pntd.0008428","journal-title":"PLoS Negl Trop Dis"},{"key":"ref32","article-title":"Mid-term Evaluation of the Global Strategy to Eliminate Yellow Fever Epidemics (EYE) 2017-2026","author":"World Health Organization","year":"2023","unstructured":"World Health Organization. Mid-term Evaluation of the Global Strategy to Eliminate Yellow Fever Epidemics (EYE) 2017-2026. World Health Organization, 2023."},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.14745\/ccdr.v36i00a11","article-title":"Statement for travellers and yellow fever: committee to advise on tropical medicine and travel","volume":"36","author":"Charlebois P","year":"2010","unstructured":"Charlebois P. Statement for travellers and yellow fever: committee to advise on tropical medicine and travel. Can Commun Dis Rep. 2010, 36:1-23. 10.14745\/ccdr.v36i00a11","journal-title":"Can Commun Dis Rep"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1093\/jtm\/taz024","article-title":"Fractional-dose yellow fever vaccination: an expert review","volume":"26","author":"Roukens AH","year":"2019","unstructured":"Roukens AH, Visser LG. Fractional-dose yellow fever vaccination: an expert review. J Travel Med. 2019, 26:taz024. 10.1093\/jtm\/taz024","journal-title":"J Travel Med"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1016\/S2214-109X(23)00594-6","article-title":"The life-long protective immunity of yellow fever vaccination: time to review?","volume":"12","author":"Juan-Giner A","year":"2024","unstructured":"Juan-Giner A, Hombach J. The life-long protective immunity of yellow fever vaccination: time to review?. Lancet Glob Health. 2024, 12:352. 10.1016\/S2214-109X(23)00594-6","journal-title":"Lancet Glob Health"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1586\/erv.12.6","article-title":"Review of the risks and benefits of yellow fever vaccination including some new analyses","volume":"11","author":"Monath TP","year":"2012","unstructured":"Monath TP. Review of the risks and benefits of yellow fever vaccination including some new analyses. Expert Rev Vaccines. 2012, 11:427-48. 10.1586\/erv.12.6","journal-title":"Expert Rev Vaccines"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1007\/s44197-025-00447-1","article-title":"Immunization coverage and barriers among Hajj and Umrah pilgrims: insights into vaccine uptake and compliance","volume":"15","author":"Bulkhi AA","year":"2025","unstructured":"Bulkhi AA, Almoallim HM, Obaid MS, et al.. Immunization coverage and barriers among Hajj and Umrah pilgrims: insights into vaccine uptake and compliance. J Epidemiol Glob Health. 2025, 15:104. 10.1007\/s44197-025-00447-1","journal-title":"J Epidemiol Glob Health"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2020.09.063","article-title":"Global assessment of national mandatory vaccination policies and consequences of non-compliance","volume":"38","author":"Gravagna K","year":"2020","unstructured":"Gravagna K, Becker A, Valeris-Chacin R, et al.. Global assessment of national mandatory vaccination policies and consequences of non-compliance. Vaccine. 2020, 38:7865-73. 10.1016\/j.vaccine.2020.09.063","journal-title":"Vaccine"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/478506-a-review-of-yellow-fever-epidemiology-pathogenesis-clinical-manifestations-treatment-prevention-and-prognosis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T05:39:57Z","timestamp":1775885997000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/478506-a-review-of-yellow-fever-epidemiology-pathogenesis-clinical-manifestations-treatment-prevention-and-prognosis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,10]]},"references-count":38,"URL":"https:\/\/doi.org\/10.7759\/cureus.106825","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4,10]]}}}